The antipyretic efficacy of propacetamol, an intravenous prodrug of paracetamol, was evaluated in two pediatric prospective randomized studies. In the first, we-compared one standard intravenous dose of propacetamol (30 mg/kg) to one standard intravenous dose of acetylsalicylic acid (ASA, 15 mg/kg) in 10 nononcologic patients with bacterial illnesses. In the second study, we compared two intravenous doses of propacetamol (30 mg/kg versus 15 mg/kg) in 24 oncologic patients with fever and neutropenia. No statistically significant differences in antipyretic efficacy were found between standard doses of propacetamol and ASA; even when half-doses of propacetamol (15 mg/kg) were used, good antipyretic efficacy was observed, which was not statistically different from that observed with the full dose. The use of propacetamol seems promising for patients (such as oncologic patients) who cannot receive enteral paracetamol formulas.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/08880019709030884 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Early palliative care in metastatic uveal melanoma (early together): protocol of a prospective randomized Phase III trial.
Melanoma Manag
December 2024
Supportive Care Dep, Institut Curie, Paris, France.
Metastatic uveal melanoma (UM) patients often initially present with limited symptoms despite a poor prognosis, complicating communication with patients and caregivers. Early Together (NCT04728113) is a randomized Phase III trial that integrates early palliative care through systematic joint visits involving the palliative care team and the medical oncologist, compared with standard oncological care, in 162 metastatic UM patients beginning systemic treatment. This collaboration aims to enhance patient functioning, improve quality of life and facilitate coping mechanisms.
View Article and Find Full Text PDFBackground: Liver malignancies present substantial challenges to surgeons due to the extensive hepatic resections required, frequently resulting in posthepatectomy liver failure. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) was designed to increase the resectable liver volume, yet it is associated with significant mortality and morbidity rates. Recently, minimally invasive techniques have been incorporated into ALPPS, with the potential to improve the procedure's safety profile whilst maintaining efficacy.
View Article and Find Full Text PDFSingle-docking robot-assisted radical antegrade modular pancreatosplenectomy with partial left nephrectomy in a patient with synchronous pancreatic neuroendocrine neoplasm and clear cell renal cell carcinoma.
J Minim Access Surg
January 2025
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
The synchronous occurrence of pancreatic neuroendocrine neoplasm (PNEN) and clear cell renal cell carcinoma (ccRCC) in one patient is extremely rare. Synchronous resection of both tumours is preferred over a two-stage procedure if possible. The robotic da Vinci Xi platform allows for multi-quadrant surgery with oncological outcomes comparable to those of laparoscopic or open surgery.
View Article and Find Full Text PDFFrontline Voice: AO Spine Member Survey Regarding Spine Oncology Knowledge Generation and Translation Needs.
Global Spine J
January 2025
NYU Langone Health, New York, NY, USA.
Study Design: cross-sectional survey.
Objectives: To evaluate AO Spine members' practices and comfort in managing metastatic and primary spine tumors, explore the use of decision-support and patient assessment tools, and identify knowledge gaps and future needs in spine oncology.
Methods: An online survey was distributed to AO Spine members to query comfort levels with key decisions in spinal oncology management, utilization of decision frameworks and spine oncology-specific instruments, and educational material preferences.
Nanoparticle-protein corona enhances accuracy of Ca-19.9-based pancreatic cancer classification.
Nanoscale
January 2025
Institute of Inorganic Chemistry, Graz University of Technology, 8010 Graz, Austria.
Among the various types of pancreatic cancers, pancreatic ductal adenocarcinoma (PDAC) is the most lethal and aggressive, due to its tendency to metastasize quickly and has a particularly low five-year survival rate. Carbohydrate antigen 19-9 (CA 19-9) is the only biomarker approved by the Food and Drug Administration for PDAC and has been a focal point in diagnostic strategies, but its sensitivity and specificity are not sufficient for early and accurate detection. To address this issue, we introduce a synergistic approach combining CA 19-9 levels with a graphene oxide (GO)-based blood test.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!